ScieGen Pharmaceuticals Inc. is recalling 66,816 bottles of Irbesartan (75 mg, 150 mg, and 300 mg) tablets sold under the Westminster Pharmaceuticals and GSMS brands. This recall was initiated after FDA testing confirmed the presence of N-nitrosodimethylamine (NDEA), an impurity that is classified as a probable human carcinogen. These prescription medications are used to treat high blood pressure and help protect kidneys in certain patients with diabetes. Consumers should not stop taking their medication without first consulting their doctor, as the risk of stopping blood pressure treatment could be higher than the risk of exposure to the impurity.
The tablets contain a chemical impurity called NDEA, which is a known environmental contaminant and is considered a probable human carcinogen. Long-term exposure to levels of NDEA above acceptable limits may increase the risk of developing cancer.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.